RSLS - ReShape Lifesciences - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RSLS is currently covered by 1 analysts with an average price target of $23121.1. This is a potential upside of $23120.75 (6605928.57%) from yesterday's end of day stock price of $0.35.

ReShape Lifesciences's activity chart (see below) currently has 4 price targets and 14 ratings on display. The stock rating distribution of RSLS is 100% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 25% with an average time for these price targets to be met of 30.75 days.

Highest price target for RSLS is $14, Lowest price target is $14.

Most recent stock forecast was given by ANTHONY VENDETTI from MAXIM GROUP on 17-Jul-2024. First documented stock forecast 31-Oct-2016.

Best performing analysts who are covering RSLS - ReShape Lifesciences:

Ben Haynor Kyle Rose Rick Wise Anthony Vendetti

Currently out of the existing stock ratings of RSLS, 1 are a HOLD (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

9 months 21 days ago
(17-Jul-2024)

0/1 (0%)

$14123 (155.59%)

Buy

2 years 11 months 12 days ago
(26-May-2022)

0/2 (0%)

$17719 (103.74%)

Hold

$8700

5 years 11 months 16 days ago
(22-May-2019)

1/1 (100%)

$-6409 (-42.42%)

123

Buy

6 years 2 months 13 days ago
(25-Feb-2019)

0/2 (0%)

$67050 (27.04%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RSLS (ReShape Lifesciences) average time for price targets to be met?

On average it took 30.75 days on average for the stock forecasts to be realized with a an average price target met ratio 25

Which analyst has the current highest performing score on RSLS (ReShape Lifesciences) with a proven track record?

BEN HAYNOR

Which analyst has the current lower performing score on RSLS (ReShape Lifesciences) with a proven track record?

ANTHONY VENDETTI

Which analyst has the most public recommendations on RSLS (ReShape Lifesciences)?

Ben Haynor works at LAKE STREET and has 17 price targets and 9 ratings on RSLS

Which analyst is the currently most bullish on RSLS (ReShape Lifesciences)?

Anthony Vendetti with highest potential upside - $0

Which analyst is the currently most reserved on RSLS (ReShape Lifesciences)?

Ben Haynor with lowest potential downside - -$0

ReShape Lifesciences in the News

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today...

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?